cytokin
addit
helper
cytokin
compar
patient
sar
mer
mani
potenti
therapi
target
host
immun
system
may
effect
inflammatori
cytokin
blockad
ifn
stem
cell
therapi
immun
cell
deplet
transfus
convalesc
plasma
artifici
extracorpor
liver
support
among
believ
blockad
promis
strategi
covidinduc
cr
notic
elev
level
consist
report
sever
studi
might
serv
predict
biomark
diseas
sever
larg
retrospect
cohort
studi
found
level
correl
mortal
patient
mechanist
essenti
gener
helper
cell
dendrit
cellt
cell
interact
excess
may
explain
overli
activ
cell
observ
patient
report
xu
et
al
although
clinic
data
blockad
viru
infectionrel
cr
unavail
anim
studi
sarscov
demonstr
inhibit
nuclear
factor
kappab
key
transcript
factor
infect
anim
sarscov
lack
coronaviru
envelop
e
protein
strong
stimulu
signal
increas
anim
surviv
reduc
level
interestingli
notic
e
protein
tocilizumab
recombin
human
monoclon
antibodi
bind
solubl
membranebound
inhibit
cisand
transsign
tocilizumab
approv
us
food
drug
administr
treatment
sever
car
cellinduc
cr
tabl
mention
earlier
cr
sever
advers
effect
induc
car
cell
therapi
incid
believ
bind
car
cell
receptor
antigen
induc
activ
bystand
cell
releas
massiv
amount
interferon
tumor
necrosi
activ
innat
immun
cell
includ
macrophag
endotheli
cell
secret
inflammatori
mediat
central
mediat
toxic
cr
level
correl
sever
car
cellinduc
cr
clinic
sever
case
cart
induc
cr
present
fever
hypoxia
acut
renal
failur
hypotens
cardiac
arrhythmia
often
warrant
icu
admiss
tocilizumab
show
promis
efficaci
sever
cr
one
two
dose
tocilizumab
patient
respond
within
day
fever
hypotens
resolv
within
hour
vasopressor
could
wean
quickli
sever
day
effect
tocilizumab
also
report
cr
relat
tocilizumab
safe
pediatr
adult
patient
advers
reaction
report
retrospect
analysi
patient
car
cellinduc
cr
common
seriou
advers
effect
infect
patient
rheumatoid
arthriti
chronic
therapi
maintain
longer
period
time
jaw
report
patient
osteoporosi
given
efficaci
tocilizumab
cr
pivot
role
covid
propos
repurpos
tocilizumab
treat
sever
case
regard
clinic
use
suggest
take
follow
factor
consider
hope
futur
clinic
trial
abl
address
diagnosi
criteria
current
consensu
diagnos
cr
earli
diagnosi
cr
patient
prompt
initi
immunomodulatori
treatment
may
benefici
suggest
experi
hlh
prompt
screen
patient
hscore
diagnost
score
hlh
may
help
discrimin
patient
cr
diseas
sever
grade
system
experi
immunotherapytrigg
cr
suggest
tocilizumab
indic
sever
case
risk
benefit
assess
favor
symptomat
manag
mild
case
approach
ration
worri
aggress
antiinflamm
principl
share
viral
infect
time
intervent
mild
moder
patient
may
prevent
progress
diseas
sever
grade
system
may
provid
object
tool
assess
appropri
time
initi
tocilizumab
treatment
current
chines
guidelin
grade
patient
mild
moder
sever
critic
vital
sign
radiograph
find
complic
current
unclear
popul
may
benefit
cautiou
cytokin
measur
cytokin
level
may
serv
biomark
risk
stratif
prognosi
previou
cohort
studi
suggest
level
significantli
elev
patient
vari
consider
among
icu
nonicu
patient
observ
rais
question
whether
blockad
effect
patient
elev
serum
level
measur
may
indispens
part
grade
system
moreov
level
alon
may
suffici
reflect
function
downstream
effect
assay
distinguish
function
total
may
provid
refin
approach
guid
therapeut
decis
creactiv
protein
crp
acutephas
inflammatori
protein
synthes
hepat
biosynthesi
reliabl
marker
bioactiv
use
predict
cr
sever
monitor
blockad
efficaci
patient
car
cellinduc
cr
crp
level
virusinduc
cr
remain
determin
studi
suggest
elev
crp
level
associ
sever
except
nevertheless
futur
studi
biomark
need
purpos
risk
stratif
therapeut
effect
monitor
also
batteri
biolog
agent
avail
target
variou
critic
molecul
inflammatori
network
tabl
tnf
ifn
janu
kinasesign
transduc
activ
transcript
jakstat
signal
agent
may
also
benefici
routin
inflammatori
cytokin
measur
warrant
origin
bat
natur
reservoir
variou
coronaviru
speci
high
genom
divers
unclear
mani
bat
coronavirus
directli
indirectli
transmiss
human
mani
potenti
caus
diseas
especi
share
viral
spike
sequenc
capabl
use
human
receptor
entri
thu
highli
like
novel
bat
coronaviru
could
caus
futur
epidem
futur
epidem
prepared
reduc
mortal
patient
global
effort
need
promot
novel
therapi
treat
virusinduc
cr
outbreak
potenti
therapi
avail
cr
summar
tabl
hope
assess
spur
futur
antiinflammatori
drug
cyclooxygenas
receptor
nuclear
factor
kappab
